Eratrectinib

Eratrectinib

Eratrectinib
Clinical data
Other namesVC004
Identifiers
  • (6R)-15-cyclopropyl-9-fluoro-2,11,15,16,20,21,24-heptazapentacyclo[16.5.2.02,6.07,12.021,25]pentacosa-1(24),7(12),8,10,18(25),19,22-heptaen-17-one
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC21H22FN7O
Molar mass407.453 g·mol−1
3D model (JSmol)
  • C1C[C@@H]2C3=C(CCN(NC(=O)C4=C5N=C(N2C1)C=CN5N=C4)C6CC6)N=CC(=C3)F
  • InChI=InChI=1S/C21H22FN7O/c22-13-10-15-17(23-11-13)5-8-28(14-3-4-14)26-21(30)16-12-24-29-9-6-19(25-20(16)29)27-7-1-2-18(15)27/h6,9-12,14,18H,1-5,7-8H2,(H,26,30)/t18-/m1/s1
  • Key:URXMBXJZRCIDQB-GOSISDBHSA-N

Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC.[1][2]

It has been approved in June 2026 for use in treating for solid tumors in China.[3]

References

  1. ^ "Eratrectinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ^ Zhou S, Zhang C, Wang G, Qian J, Huang G, Wang J, et al. (June 2026). "Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study". Experimental Hematology & Oncology. doi:10.1186/s40164-026-00799-9. PMID 42351304.
  3. ^ "NMPA Approves Vcare's Eratrectinib for NTRK Tumors". AllSci. 5 June 2026.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.